There are ongoing phase-II clinical trials (NCT03680508) using TSR-042 PDCD1 (PD-1) and TSR-022 anti-HAVCR2 (TIM3) antibodies for primary liver cancer. This evidence concerns the gene HAVCR2 and liver cancer.